Our Clinical Trials

OUR CLINICAL TRIALS

Advancing oncology at the speed of life™ APOPTOSIS HEMATOPOIESIS AMG 176 (MCL-1 inhibitor) Romiplostim (thrombopoiesis stimulator) Research Area Description Phase Status NCT/Amgen ID* Research Area Description Phase Status NCT/Amgen ID*

AML, First-in-Human Study of AMG 176 in Relapsed or Single-Arm, Open-Label, Long-Term Study of 02675452 02279173 Multiple Refractory Multiple Myeloma and in Relapsed or 1 ITP Romiplostim in Thrombocytopenic Pediatric 3 20150161 20101221 Myeloma Refractory AML Patients With ITP

Study of Romiplostim for Chemotherapy 03362177 AMG 397 (MCL-1 inhibitor) Solid Tumors Induced Thrombocytopenia in Patients With 3 20140346 Research Area Description Phase Status NCT/Amgen ID* Gastrointestinal or Colorectal Cancer

AML, Multiple Safety, Tolerability, Pharmacokinetics and 03465540 Myeloma, Efficacy of AMG 397, an Oral MCL1 Inhibitor, in 1 20170173 Pegfilgrastim(granulocyte colony-stimulating factor) NHL Patients With Multiple Myeloma, NHL, and AML Research Area Description Phase Status EU PAS/Amgen ID‡

Prospective Observational Study to Estimate † BIOSIMILARS Incidence of Febrile Neutropenia in High Risk Patients with Non-myeloid Malignancies 24626 ABP 798 (biosimilar rituximab; anti-CD20 antibody) FN Observational Receiving Pegfilgrastim OBI (Onbody Injector) 20170758 Research Area Description Phase Status NCT/Amgen ID* or Physician Choice for Febrile Neutropenia Prophylaxis Efficacy and Safety Study of ABP 798 Compared 02747043 NHL With Rituximab in Treating Non-Hodgkin 3 20130109 Lymphoma (JASMINE) IMMUNOTHERAPY ABP 959 (Biosimilar eculizumab; anti-complement C5 antibody) AMG 119 (Anti-DLL3 CAR T) Research Area Description Phase Status NCT/Amgen ID* Research Area Description Phase Status NCT/Amgen ID*

Paroxysmal Efficacy and Safety of ABP 959 Compared With First-in-Human Study of AMG 119 in Patients 03392064 03818607 SCLC 1 Nocturnal Eculizumab in Adult Participants With PNH 3 With RR SCLC 20170124 20150168 Hemoglobinuria (DAHLIA)

AMG 160 (Half-life extended BiTE® molecule targeting PSMA) ABP 980 (Biosimilar trastuzumab; anti-HER2 antibody) Research Area Description Phase Status NCT/Amgen ID* Research Area Description Phase Status NCT/Amgen ID* Prostate Safety, Tolerability, Pharmacokinetics, and 03792841 Efficacy and Safety Study of ABP 980 Compared 1 01901146 Cancer Efficacy of AMG 160 in Patients with mCRPC 20180101 Breast Cancer With Trastuzumab in Subjects With HER2 3 20120283 Positive Early Breast Cancer (Lilac) AMG 330 (BiTE® molecule targeting CD33) BONE METASTASES AND METABOLISM Research Area Description Phase Status NCT/Amgen ID* Denosumab (RANK-ligand inhibitor) First-in-Human Study of AMG 330 in Adult 02520427 AML 1 Research Area Description Phase Status NCT/Amgen ID* Patients With Relapsed or Refractory AML 20120252

Denosumab Compared to Zoledronic Acid in Multiple 01345019 the Treatment of Bone Disease in Patients With 3 Myeloma 20090482 AMG 404 (Anti-PD1 antibody) Multiple Myeloma Research Area Description Phase Status NCT/Amgen ID* Long-term Safety Follow-up of Subjects With Giant Cell 03301857 Safety, Tolerability, Pharmacokinetics and Giant Cell Tumor of Bone Treated With 4 Advanced 03853109 Tumor of Bone 20140114 Pharmacodynamics of AMG 404, in Patients 1 Denosumab in Study 20062004 Solid Tumors 20180143 With Advanced Solid Tumors 01666106 Osteonecrosis of the Jaw (ONJ) Case Registry Registry 20101102 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) and Infection 01967160 Among Nordic Cancer Patients Treated With Observational 20101363 XGEVA™ or Zoledronic Acid Not yet recruiting Active, recruiting Active, not recruiting Completed, pending results IMMUNOTHERAPY, continued IMMUNOTHERAPY, continued AMG 420§ (BiTE® molecule targeting BCMA) AMG 757 (Half-life extended BiTE® molecule targeting DLL3) Research Area Description Phase Status NCT/Amgen ID* Research Area Description Phase Status NCT/Amgen ID*

Dose Escalation Study of IV BI 836909 03319940 02514239 SCLC First-in-Human Study of AMG 757 in SCLC 1 (AMG 420) Monotherapy in Patients With 1 20160323 N/A Multiple Relapsed and/or Refractory Multiple Myeloma** Myeloma Assessment of AMG 420 in Subjects With 03836053 Blinatumomab (BiTE® molecule targeting CD19) 1 Relapsed and/or Refractory Multiple Myeloma 20160370 Research Area Description Phase Status NCT/Amgen ID*

Study of Blinatumomab in Japanese Patients 02412306 ® 1b/2 AMG 424 (Anti-CD38 XmAb ) With Relapsed or Refractory B-Precursor ALL 20130265 Research Area Description Phase Status NCT/Amgen ID* Blinatumomab vs Standard Chemotherapy in 02393859 Multiple First-in-Human Study of AMG 424 in Patients 03445663 Pediatric Patients With High Risk First Relapse 3 1 20120215 Myeloma With Multiple Myeloma 20160445 B-Precursor ALL

Study of Blinatumomab in Chinese Adult Patients 03476239 ® 3 AMG 427 (Half-life extended BiTE molecule targeting FLT3) With Relapsed or Refractory B-precursor ALL 20130316 * Research Area Description Phase Status NCT/Amgen ID ALL Observational Study of Patients With Philadelphia 02783651 First-in-Human Study of AMG 427 in Patients 03541369 Chromosome-Negative Relapsed or Refractory Registry AML 1 20150253 With Relapsed/Refractory Acute Myeloid Leukemia 20170528 ALL in the US

Expanded Access Protocol of Blinatumomab in 02187354 AMG 553 (Anti-FLT3 CAR T) Pediatric and Adolescent Patients With Relapsed 4 Available 20130320 Research Area Description Phase Status NCT/Amgen ID* or Refractory B-Precursor ALL (RIALTO)

First in Human Study of AMG 553 in 03904069 03117621 AML 1 Observational Study of Blinatumomab 4 Patients With Acute Myeloid Leukemia 20180091 20150136

Safety and PK of Subcutaneous Blinatumomab in 02961881 ® 1b AMG 562 (Half-life extended BiTE molecule targeting CD19) Relapsed or Refractory Indolent NHL 20140286 Research Area Description Phase Status NCT/Amgen ID* Efficacy and Safety of Blinatumomab in Combination With Pembrolizumab in Adult 03340766 First-in-Human Study of AMG 562 in Patients 1b With Relapsed or Refractory Diffuse Large B-Cell 03571828 Patients With Relapsed or Refractory DLBCL 20150290 NHL 1 Lymphoma, Mantle Cell Lymphoma, or Follicular 20170533 (KEYNOTE-348) Lymphoma NHL Efficacy and Safety of Blinatumomab in Patients 03023878 2 With Newly Diagnosed High-Risk DLBCL 20150288 AMG 596 (BiTE® molecule targeting EGFRvIII) Effect of Blinatumomab on Minimal Residual Research Area Description Phase Status NCT/Amgen ID* 03298412 Disease in Patients With DLBCL Post-Autologous 2 20150291 First-in-Human Study of AMG 596 in Adult 03296696 Hematopoietic Stem-Cell Transplantation Glioblastoma 1 Patients With EGFRvIII Positive Glioblastoma 20160132 Efficacy and Safety of Blinatumomab in Patients 02910063 2/3 With Relapsed or Refractory Aggressive B-Cell NHL 20150292 AMG 673 (Half-life extended BiTE® molecule targeting CD33) Research Area Description Phase Status NCT/Amgen ID* Talimogene Laherparepvec†† (oncolytic viral immunotherapy) First-in-Human Study of AMG 673 in Adult 03224819 Research Area Description Phase Status NCT/Amgen ID* AML 1 Patients With Relapsed or Refractory AML 20160377 Advanced Non Study of Talimogene Laherparepvec in Children 02756845 1 CNS Tumors With Advanced Non-CNS Tumors 20110261 AMG 701 (Half-life extended BiTE® molecule targeting BCMA) Research Area Description Phase Status NCT/Amgen ID*

Multiple First-in-Human Study of AMG 701 in Multiple 03287908 1 Myeloma Myeloma 20170122 Not yet recruiting Active, recruiting Active, not recruiting Completed, pending results IMMUNOTHERAPY, continued PROTEIN DEGRADATION, continued Talimogene Laherparepvec†† (oncolytic viral immunotherapy) Carfilzomib‡‡ (proteasome inhibitor) continued Research Area Description Phase Status NCT/Amgen ID* Research Area Description Phase Status NCT/Amgen ID*

Study to Evaluate the Safety/Efficacy of Real-world Use of Carfilzomib Among Patients 03091127 Observational T-VEC in Japanese Subjects With 03064763 With Relapsed MM in Europe 20150262 1 Unresectable Stage IIIB-IV Malignant 20140270 Study of Carfilzomib Administered Once Melanoma 02335983 Weekly in Combination With Lenalidomide and 1b CFZ013 Ipilimumab With or Without Talimogene 01740297 Dexamethasone in Patients With Multiple Myeloma 1b/2 Laherparepvec in Unresected Melanoma 20110264 Multiple A Study of Carfilzomib Plus Dexamethasone in Myeloma 03512353 Efficacy and Safety of Talimogene Laherparepvec Subjects With Relapsed or Refractory Multiple 2 02211131 20170596 Neoadjuvant Treatment Plus Surgery Versus 2 Myeloma at US Community Oncology Centers 20110266 Surgery Alone for Melanoma Study Comparing Carfilzomib, Dexamethasone, Single-Arm Trial to Evaluate the Biodistribution 02014441 and Daratumumab to Carfilzomib and 03158688 2 3 and Shedding of Talimogene Laherparepvec 20120324 Dexamethasone in Relapsed or Refractory 20160275 Melanoma Multiple Myeloma (CANDOR) Single-Arm Trial to Evaluate the Role of the 02366195 Immune Response to Talimogene Laherparepvec 2 20120325 in Unresected Melanoma TUMOR REGULATION

Pembrolizumab With or Without Talimogene 02263508 AMG 510 (KRAS G12C Inhibitor) 3 Laherparepvec in Unresected Melanoma 20110265 Research Area Description Phase Status NCT/Amgen ID*

Postmarketing Prospective Study of Melanoma First-in-Human Study of AMG 510 in Patients 03600883 02910557 Solid Tumors 1 Patients Treated With Talimogene Laherparepvec 4 With Solid Tumors With KRAS G12C Mutation 20170543 20130193 to Characterize Risk of Herpetic Infection

Registry Study to Evaluate the Survival and Long- Enrolling 02173171 IMMUNE MODULATION Term Safety of Patients With Melanoma Who Registry by invitation 20120139 Previously Received Talimogene Laherparepvec only AMG 592 (IL-2 mutein) Research Area Description Phase Status NCT/Amgen ID* Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous 02626000 Open-label Study Evaluating the Safety, HNSCC 1b Chronic Graft Tolerability, Pharmacokinetics, Cell Carcinoma of the Head and Neck 20130232 03422627 Versus Host Pharmacodynamics, and Efficacy of 1b/2 (MASTERKEY232/KEYNOTE-137) 20160283 Disease AMG 592 in Adult Patients With Steroid Safety Study of Talimogene Laheraprepvec Refractory Chronic Graft Versus Host Disease 02509507 Injected into Hepatocellular Carcinoma and 1b 20140318 Metastatic Liver Tumors *For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgentrials.com. Solid Tumors †The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference Safety Study of Talimogene Laherparepvec indications with scientific justification. Combined With Atezolizumab for Triple Negative 03256344 ‡ 1b For detailed information on this study please visit http://www.encepp.eu/encepp/studiesDatabase.jsp. Breast Cancer and Colorectal Cancer With Liver 20140299 §As of September 1, 2016, Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI Metastases 836909 (AMG 420). **This study is sponsored by Boehringer Ingelheim ††Previously referred to as OncoVEXGM-CSF. PROTEIN DEGRADATION ‡‡Sponsored by Onyx Pharmaceuticals, an Amgen subsidiary. XmAb® is a registered trademark of Xencor. ‡‡ Carfilzomib (proteasome inhibitor) ALL – acute lymphoblastic leukemia; AML – acute myelogenous leukemia; BiTE® – bispecific T cell engager; CNS – central nervous

* system; DLBCL – diffuse large B-cell lymphoma; EGFR – epidermal growth factor receptor; EGFRvIII – epidermal growth factor Research Area Description Phase Status NCT/Amgen ID receptor variant III; FN – febrile neutropenia; HNSCC – head and neck squamous cell carcinoma; ITP – immune thrombocytopenic purpura; IV – intravenous; mAb – monoclonal antibody; mCRC – metastatic colorectal cancer; NHL – non-hodgkin lymphoma; Carfilzomib in Combination With Induction 02303821 ORR – objective response rate; PK – pharmacokinetics; QoL – quality of life; SCLC – small cell lung cancer. ALL Chemotherapy in Children With Relapsed or 1b CFZ008 Refractory ALL Information as of April 5, 2019. Statements are based on the company’s current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen’s filings with the SEC. Products under investigational study have not been approved by regulatory agencies for the use under investigation. This information is provided only for purposes of providing general information on clinical trials and stages of development on the select candidates identified. This information should not be construed as a recommendation for use of any product for unapproved uses.

Not yet recruiting Active, recruiting Active, not recruiting Completed, pending results Amgen’s Research and Development Guiding Principles

Amgen aspires to be the best human therapeutics company. Achieving this goal starts with building the world’s premier R&D organization. Amgen’s R&D Guiding Principles were inspired by this pursuit and designed to reinforce our strategic priorities. Focus on innovative medicines for unmet needs in patients with serious illnesses. While Amgen is always pursuing new opportunities and adapting to challenges, we retain an enduring commitment to the same mission. That mission is to enhance and extend the lives of patients facing serious illness. Pursue targets that are validated in humans. We believe we are on the threshold of a revolution in science in which population genetics will help to reveal new targets that clearly drive disease risk in humans. By focusing on targets supported by human genetics or other strong human evidence, we aim to increase our clinical success rates, reduce development timelines, and lower the cost of delivering new medicines to patients. Maintain an expansive toolkit of drug modalities with a focus on biologics. Amgen pursues a “biology-first” approach to drug discovery. We strive to select drug targets based on a deep understanding of disease biology, and then choose the drug modality, or structural template, best suited to the target. We recognize our strength in biologics and the higher clinical success rates for biologic medicines. We also maintain a broad toolkit of modalities, including small molecules, in order to have the right tool for any target we pursue. Focus on return on investment and operational efficiency.To maximize the value of Amgen’s R&D investment, we focus resources on programs that offer a large effect size and more likelihood of success. We maximize the value of lower-priority assets by partnering and out-licensing. Amgen also strives to continually identify operational efficiencies, such as reduced cycle times, leaner clinical trials, and centralized monitoring of clinical study sites. Harness external innovation. At Amgen, we pursue great innovation wherever we can find it, and roughly half of our current late-stage pipeline comes from collaborations or acquisitions. We appreciate the synergy between in-house and external innovation: To identify and add value to the best external inventions, we need to maintain a high level of in-house scientific talent and capabilities. Demonstrate the value of our medicines. Patients will not benefit from medicines they cannot access, and increasingly, access depends on meeting evolving standards from regulators and payers. To meet these expectations, we strive to deliver major therapeutic advances—medicines that offer compelling benefits for patients and sound health economics for society.